As of November 6, 2026, 2 holders' latest Schedule 13D or 13G filings report owning 5% or more of Tenaya Therapeutics, Inc. The largest reported stake is The Column Group III, LP's, at 23.1%. 7 filings are on record since July 16, 2025 (Schedule 13D/A, February 26, 2026).
Sell to companies like Tenaya Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Integrated Core Strategies (US) LLC · Sole voting: 0 · Shared voting: 11,579,445 · Sole dispositive: 0 · Shared dispositive: 11,579,445 · SCHEDULE 13G, 2026-08-24
- · Reporting person: The Column Group III, LP · Sole voting: 0 · Shared voting: 0 · Sole dispositive: 0 · Shared dispositive: 0 · SCHEDULE 13D/A, 2026-02-26
- · Holder: The Column Group III, LP · Percent: 25.4% · SCHEDULE 13D/A
- · Holder: The Column Group III, LP · Percent: 23.1% · SCHEDULE 13D/A
- · Holder: Woodline Partners LP · Percent: 4.99% · SCHEDULE 13G/A
Tenaya Therapeutics, Inc. has 7 Schedule 13D or 13G filings on record since 2025-07-16. 2 holders' latest filing reports 5% or more of common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| The Column Group III, LP | 23.1% | 0 | SCHEDULE 13D/A, 2026-02-26 | 2026-02-25 |
| Integrated Core Strategies (US) LLC | 5.2% | 11,579,445 | SCHEDULE 13G, 2026-08-24 | 2026-08-17 |
| Empery Asset Management, LP | 4.99% | 8,296,276 | SCHEDULE 13G/A, 2025-07-31 | 2025-06-30 |
| Woodline Partners LP | 4.99% | 9,000,000 | SCHEDULE 13G/A, 2025-08-14 | 2025-06-30 |
| BlackRock, Inc. | 1.7% | 2,732,800 | SCHEDULE 13G/A, 2025-07-16 | 2025-06-30 |
Holding shares or following this stake? See who's behind Tenaya Therapeutics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Tenaya Therapeutics, Inc. and the records around it.
Tenaya Therapeutics, Inc. elsewhere on the record
- Leadership changes Jun 2026
- Who owns it
Companies that share a holder
- Woodline Partners LP also filed stake reports on 19 other companies: Biohaven Ltd. (Aug 2026), Black Rock Coffee Bar, Inc. (Aug 2026), CalciMedica, Inc. (Aug 2026)
- Empery Asset Management, LP also filed stake reports on 21 other companies: Dyadic International Inc. (Oct 2026), Femasys Inc. (Oct 2026), Clene Inc. (Oct 2026)
- Integrated Core Strategies (US) LLC also filed stake reports on 63 other companies: SkinHealth Systems Inc. (Nov 2026), Infinite Eagle Acquisition Corp. (Nov 2026), Longeveron Inc. (Nov 2026)
Watch Tenaya Therapeutics, Inc.
Get an email when Tenaya Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Tenaya Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Tenaya Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Tenaya Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
8 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| The Column Group III, LP | 0 | 0 | 0 | 0 | SCHEDULE 13D/A, 2026-02-26 |
| The Column Group III-A, LP | 0 | 0 | 0 | 0 | SCHEDULE 13D/A, 2026-02-26 |
| The Column Group III GP, LP | 0 | 0 | 0 | 0 | SCHEDULE 13D/A, 2026-02-26 |
| The Column Group Opportunity III, LP | 0 | 49,313,559 | 0 | 49,313,559 | SCHEDULE 13D/A, 2026-02-26 |
| The Column Group Opportunity III GP, LP | 0 | 49,313,559 | 0 | 49,313,559 | SCHEDULE 13D/A, 2026-02-26 |
| TCG Opportunity III GP, LLC | 0 | 49,313,559 | 0 | 49,313,559 | SCHEDULE 13D/A, 2026-02-26 |
| Tim Kutzkey | 0 | 49,313,559 | 0 | 49,313,559 | SCHEDULE 13D/A, 2026-02-26 |
| Peter Svennilson | 0 | 49,313,559 | 0 | 49,313,559 | SCHEDULE 13D/A, 2026-02-26 |
| Integrated Core Strategies (US) LLC | 0 | 11,579,445 | 0 | 11,579,445 | SCHEDULE 13G, 2026-08-24 |
| Millennium Management LLC | 0 | 11,581,565 | 0 | 11,581,565 | SCHEDULE 13G, 2026-08-24 |
| Millennium Group Management LLC | 0 | 11,581,565 | 0 | 11,581,565 | SCHEDULE 13G, 2026-08-24 |
| Israel A. Englander | 0 | 11,581,565 | 0 | 11,581,565 | SCHEDULE 13G, 2026-08-24 |
The latest filing identifies Tenaya Therapeutics, Inc. by CUSIP 87990A106 and gives its principal executive office as 171 Oyster Point Boulevard, Suite 500, South San Francisco, CA 94080 (SCHEDULE 13G, 2026-08-24).
Source of funds (Item 3)
Item 3 of the Original Schedule 13D is hereby amended by adding the following as the last paragraphs thereof: On February 20, 2026, TCG III LP sold an aggregate of 245,965 shares of the Issuer's Common Stock at a weighted-average price of $0.6149 per share and an aggregate sale price of approximately $0.15 million. On February 20, 2026, TCG III-A LP sold an aggregate of 277,769 shares of the Issuer's Common Stock at a weighted-average price of $0.6149 per share and an aggregate sale price of approximately $0.17 million.The Column Group III, LP, SCHEDULE 13D/A, 2026-02-26
Purpose of Transaction (Item 4)
The Column Group III, LP
The information set forth in Item 4 of the Original Schedule 13D is incorporated herein by reference.Item 4 of the SCHEDULE 13D/A filed 2026-02-26
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-16 | BlackRock, Inc. | 1.7% | SCHEDULE 13G/A |
| 2025-07-31 | Empery Asset Management, LP | 4.99% | SCHEDULE 13G/A |
| 2025-08-14 | Woodline Partners LP | 4.99% | SCHEDULE 13G/A |
| 2025-12-17 | The Column Group III, LP | 23.1% | SCHEDULE 13D/A |
| 2026-02-12 | The Column Group III, LP | 25.4% | SCHEDULE 13D/A |
| 2026-02-26 | The Column Group III, LP | 23.1% | SCHEDULE 13D/A |
| 2026-08-24 | Integrated Core Strategies (US) LLC | 5.2% | SCHEDULE 13G |
Questions about who owns Tenaya Therapeutics, Inc.
Who owns Tenaya Therapeutics, Inc.?
On this page, 2 holders' latest ownership filings report 5% or more of Tenaya Therapeutics, Inc.: The Column Group III, LP (23.1%, Schedule 13D/A, filed 2026-02-26) and Integrated Core Strategies (US) LLC (5.2%, Schedule 13G, filed 2026-08-24).
Who are the largest shareholders of Tenaya Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Tenaya Therapeutics, Inc. on this page are The Column Group III, LP (23.1%) and Integrated Core Strategies (US) LLC (5.2%).
When did The Column Group III, LP buy into Tenaya Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from The Column Group III, LP on this page is the Schedule 13D/A, filed 2025-12-17, reporting 23.1%; its latest, Schedule 13D/A filed 2026-02-26, reports 23.1%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 7 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Tenaya Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| June 29, 2026 | Leadership change: Eric Hyllengren appointed, Chief Financial Officer | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Tenaya Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.